On the companies front, three out of 12 companies are likely to report 15%+ YoY growth. Key monitorables are: Lupin, likely to register above 21% growth amid one-off US$50 million licensing income and strong domestic growth. Amid lower base, Sun Pharma and Apollo Hospitals are likely to...